One of the world's largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

DUBLIN - July 17, 2017 - Medtronic plc (MDT) today announced that the InterStim(TM) system, which provides sacral neuromodulation therapy, offers sustained long-term efficacy and quality of life ...

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with Bladder and Bowel Control Issues SureScan™ MRI Leads Will Provide Full-Body MRI Conditional Labeling The rechargeable ...

Intuitive and Discreet Device Provides Sacral Neuromodulation Therapy for Overactive Bladder and Bowel Incontinence DUBLIN - December 17, 2018 - Medtronic plc (MDT) today announced U.S. Food and Drug ...

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) approval of InterStim® Therapy for Bowel Control. InterStim Therapy, previously ...

One of the world’s largest medical technology, services and solutions companies, Medtronic plc MDT is making efforts to expand its Pelvic Health & Gastric Therapies business, part of the company's ...

Joseph Welles Henderson, MD, of University Hospitals has been named an InterStim™ Center of Excellence by Medtronic (NYSE: MDT), the world’s largest medical device manufacturer. The designation is ...

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...

The FDA has issued Medtronic clearance to market the InterStim sacral nerve stimulation therapy system for people with chronic fecal incontinence. The pacemaker-like device has already been FDA ...

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...